ArticleNeuropsychiatric disease and treatment2022

Efficacy and Safety of Low-Dose Rituximab in Anti-MuSK Myasthenia Gravis Patients: A Retrospective Study.

Xin Meng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.